Transplantation for multiple myeloma: Who, when, how often?

TY - JOUR

T1 - Transplantation for multiple myeloma

T2 - Who, when, how often?

AU - Bladé, Joan

AU - Vesole, David H.

AU - Gertz, Morie

PY - 2003/11/15

Y1 - 2003/11/15

N2 - The outcome of phtients with multiple myeloma (MM) is unsatisfactory, with a median survival of less than 3 years.1,2 The prospects for survival at 10 years are poor with conventional chemotherapy.3,4 The limited efficacy of conventional treatment prompted the introduction of high-dose therapy (HDT) followed by stem cell support in an attempt to achieve a greater tumor reduction with longer disease-free and overall survival (OS). Not all patients in whom HDT is feasible obtain a significant benefit from the procedure.

AB - The outcome of phtients with multiple myeloma (MM) is unsatisfactory, with a median survival of less than 3 years.1,2 The prospects for survival at 10 years are poor with conventional chemotherapy.3,4 The limited efficacy of conventional treatment prompted the introduction of high-dose therapy (HDT) followed by stem cell support in an attempt to achieve a greater tumor reduction with longer disease-free and overall survival (OS). Not all patients in whom HDT is feasible obtain a significant benefit from the procedure.

UR - https://www.scopus.com/pages/publications/0242579413

U2 - 10.1182/blood-2003-01-0073

DO - 10.1182/blood-2003-01-0073

M3 - Review article

C2 - 12893762

SN - 0006-4971

VL - 102

SP - 3469

EP - 3477

JO - Blood

JF - Blood

IS - 10

ER -